Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/733
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMyers, Ken-
dc.contributor.otherJolley, Damien-
dc.date2008-08-
dc.date.accessioned2016-08-30T02:27:27Z-
dc.date.available2016-08-30T02:27:27Z-
dc.date.issued2008-11-
dc.identifier.citationEur J Vasc Endovasc Surg. 2008 Nov;36(5):602-5en_US
dc.identifier.issn1078-5884en_US
dc.identifier.issn1532-2165en_US
dc.identifier.urihttp://hdl.handle.net/11434/733-
dc.description.abstractOBJECTIVE: To determine which covariates predisposed to deep venous occlusion (DVO) after ultrasound-guided sclerotherapy (UGS) for varicose veins. DESIGN: Ultrasound scans before and at 3 to 7 days after UGS to detect post-procedure deep venous occlusion. MATERIALS: A consecutive series of 1931 treatment sessions in 852 patients treated by a technique for UGS. METHODS: Ultrasound examination of the full length of axial deep veins above and below knee before and soon after every procedure. Crude chi(2) analysis of all covariates allowed selection of those that showed apparent significant influence. Logistic regression analysis of these then determined which independently predisposed to post-procedure deep venous occlusion. RESULTS: Deep venous occlusion was only observed after UGS using foamed sclerosant and occurred following 28 treatment sessions. No significant difference for risk of deep venous occlusion was observed for patient characteristics or which veins were treated. Logistic regression analysis showed significant independent increased risk in a limb from using highly diluted or undiluted sclerosant (OR 0.55; 95% CI 0.19 to 1.59 for 0.6-1.0% solution, OR 10.45; 95% CI 3.12 to 34.99 for 2-2.3% and OR 0.36; 95% CI 0.07 to 1.74 for 3% solution), treating veins >or=5mm diameter (OR 3.70; 95% CI 1.23 to 11.13) and injecting >or=10 ml of foamed sclerosant for a limb (OR 3.64; 95% CI 1.21 to 10.90). CONCLUSIONS: The risk of deep venous occlusion after UGS in this series was lower when using highly diluted or undiluted sclerosant, when treating veins less than 5mm in diameter and when restricting the volume of foam injected to less than 10 ml.en_US
dc.publisherElsevieren_US
dc.relation.urihttp://www.sciencedirect.com/science/article/pii/S107858840800364X-
dc.subjectSclerosing Solutionsen_US
dc.subjectSclerotherapyen_US
dc.subjectUltrasonographyen_US
dc.subjectVaricose Veinsen_US
dc.subjectVenous Thrombosisen_US
dc.subjectDeep Vein Thrombosisen_US
dc.subjectDeep Venous Occlusionen_US
dc.subjectDVOen_US
dc.subjectUltrasound Guided Sclerotherapyen_US
dc.subjectUGSen_US
dc.subjectVictoria Vein Clinic, Epworth HealthCare, Australiaen_US
dc.subjectUroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleFactors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.ejvs.2008.06.026en_US
dc.identifier.journaltitleEuropean Journal of Vascular and Endovascular Surgeryen_US
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/18718772en_US
dc.type.studyortrialCohort Studyen_US
dc.type.contenttypeTexten_US
Appears in Collections:Diagnostic Services
UroRenal, Vascular

Files in This Item:
File Description SizeFormat  
Factors Affecting the Risk of Deep Venous Occlusion.pdf99.94 kBAdobe PDFView/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.